EHL BIO overview
Stem-cell approach for Chronic Kidney Disease
EHL reports that urine-derived stem cells are collected non-invasively, originate from the kidney and secrete Klotho, which suppressed renal fibrosis in animal models. KDSTEM is in clinical research; participation and eligibility must be confirmed with EHL.
Cell technology and manufacturing
EHL BIO publishes information on cell isolation, culture, banking and quality control through its GMP centre.
View EHL technologyAssessment at EHL Cell Clinic
A clinician must assess the condition, overall health, treatment history and fit with an applicable Korean plan for each patient.
Meet the hospital and care teamKorean regenerative-medicine law
Korea provides a regulated advanced regenerative-medicine treatment pathway
Korea's amended law, effective 21 February 2025, allows designated advanced regenerative-medicine institutions to submit treatment plans for committee review and charge for treatment delivered under a plan found suitable.
The law does not automatically authorise every stem-cell type for every disease. Access depends on the institution's status, cell type, condition, a suitable reviewed plan and individual patient assessment.
Frequently asked questions
Original EHL BIO disease source
https://www.ehlbio.co.kr/support/news/?v=31Information sources
- Korean National Law Information Center — Advanced Regenerative Bio Act · retrieved 11 Oct 2026
- K-ARM — Advanced regenerative-medicine treatment plan review · retrieved 11 Oct 2026
- Korean Ministry of Health and Welfare — designated institutions and treatment plans · retrieved 11 Oct 2026